Indoximod - NewLink Genetics Corporation

Drug Profile

Indoximod - NewLink Genetics Corporation

Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-8189; NSC-721782

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer National Cancer Institute (USA); NewLink Genetics Corporation; University of Minnesota
  • Class Amino acids; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Glioma; Malignant melanoma; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 30 Oct 2017 Indoximod receives Orphan Drug status for Malignant melanoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top